| 51 |
30217442 | BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells. | 2018 Oct 12 |
1 |
| 52 |
30705677 | NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. | 2018 |
1 |
| 53 |
31249931 | BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? | 2018 Jan |
1 |
| 54 |
27686674 | Constitutional t(8;22)(q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosome-positive chronic myeloid leukemia. | 2017 Feb |
1 |
| 55 |
27852118 | Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. | 2017 Jan |
1 |
| 56 |
28224300 | Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. | 2017 Jul |
1 |
| 57 |
28349229 | MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. | 2017 Aug |
1 |
| 58 |
28601294 | The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia. | 2017 Aug 15 |
2 |
| 59 |
28706179 | Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature. | 2017 Jul 14 |
1 |
| 60 |
28757617 | Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. | 2017 Nov |
1 |
| 61 |
28801986 | Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response. | 2017 Nov |
1 |
| 62 |
26479578 | In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study. | 2016 Oct |
1 |
| 63 |
26582603 | Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. | 2016 Apr |
1 |
| 64 |
26607600 | Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. | 2016 Apr 15 |
1 |
| 65 |
26847385 | Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report. | 2016 Mar |
1 |
| 66 |
27044711 | A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | 2016 Jul |
2 |
| 67 |
27194977 | Nilotinib-Induced Keratosis Pilaris. | 2016 Jan-Apr |
2 |
| 68 |
27293031 | Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling. | 2016 Jun 13 |
2 |
| 69 |
27434297 | Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. | 2016 Jul 11 |
3 |
| 70 |
27583255 | Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. | 2016 |
1 |
| 71 |
27821800 | Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. | 2016 Nov 29 |
2 |
| 72 |
27864817 | Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy. | 2016 Dec |
1 |
| 73 |
28191543 | The third-time chronic myeloid leukemia in lymphoblastic crisis with ABL1 kinase mutation induced by decitabine, dexamethason combined with nilotinib and dasatinib. | 2016 Dec 1 |
1 |
| 74 |
25527332 | The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. | 2015 Jan |
1 |
| 75 |
25721903 | Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation. | 2015 |
1 |
| 76 |
25803821 | ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines. | 2015 |
1 |
| 77 |
25882987 | Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. | 2015 May |
1 |
| 78 |
25889792 | The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. | 2015 Mar 24 |
2 |
| 79 |
25900790 | Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement. | 2015 Aug |
1 |
| 80 |
26139550 | [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia]. | 2015 Jul |
1 |
| 81 |
26195136 | Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. | 2015 Sep 1 |
1 |
| 82 |
26266095 | Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis. | 2015 |
1 |
| 83 |
26473951 | Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release. | 2015 |
1 |
| 84 |
26622510 | Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report. | 2015 Oct |
3 |
| 85 |
24100660 | Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. | 2014 Feb |
2 |
| 86 |
24143950 | BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia. | 2014 Jul |
1 |
| 87 |
24258348 | Ever-advancing chronic myeloid leukemia treatment. | 2014 Feb |
1 |
| 88 |
24333114 | Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response. | 2014 Mar |
1 |
| 89 |
24412932 | c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. | 2014 Jun 1 |
2 |
| 90 |
24651611 | Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells. | 2014 Mar 19 |
2 |
| 91 |
24662807 | Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans. | 2014 Jul |
1 |
| 92 |
24756785 | Nilotinib. | 2014 |
1 |
| 93 |
24786396 | The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. | 2014 May 2 |
1 |
| 94 |
24789045 | Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. | 2014 |
1 |
| 95 |
24847647 | New resistance mechanisms for small molecule kinase inhibitors of Abl kinase. | 2014 Mar |
1 |
| 96 |
24865254 | Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach. | 2014 Jul 7 |
4 |
| 97 |
25006277 | Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting. | 2014 Jan |
1 |
| 98 |
25025064 | Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation. | 2014 |
3 |
| 99 |
25038611 | In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. | 2014 Aug |
1 |
| 100 |
25116401 | Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment. | 2014 |
1 |